EP1463524A4 - Methodes therapeutiques de traitement d'un lymphome non hodgkinien - Google Patents

Methodes therapeutiques de traitement d'un lymphome non hodgkinien

Info

Publication number
EP1463524A4
EP1463524A4 EP02797231A EP02797231A EP1463524A4 EP 1463524 A4 EP1463524 A4 EP 1463524A4 EP 02797231 A EP02797231 A EP 02797231A EP 02797231 A EP02797231 A EP 02797231A EP 1463524 A4 EP1463524 A4 EP 1463524A4
Authority
EP
European Patent Office
Prior art keywords
hodgkin
lymphoma
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02797231A
Other languages
German (de)
English (en)
Other versions
EP1463524A2 (fr
Inventor
Maurice J Wolin
Sandra Milan
Deborah Hurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1463524A2 publication Critical patent/EP1463524A2/fr
Publication of EP1463524A4 publication Critical patent/EP1463524A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02797231A 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien Withdrawn EP1463524A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17968 1998-02-03
US293664 1999-04-16
US1796801A 2001-12-07 2001-12-07
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
PCT/US2002/039253 WO2003049694A2 (fr) 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien

Publications (2)

Publication Number Publication Date
EP1463524A2 EP1463524A2 (fr) 2004-10-06
EP1463524A4 true EP1463524A4 (fr) 2005-02-09

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02797231A Withdrawn EP1463524A4 (fr) 2001-12-07 2002-12-06 Methodes therapeutiques de traitement d'un lymphome non hodgkinien

Country Status (5)

Country Link
EP (1) EP1463524A4 (fr)
JP (1) JP2005538034A (fr)
AU (1) AU2002362098A1 (fr)
CA (1) CA2469045A1 (fr)
WO (1) WO2003049694A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0316779B8 (pt) 2002-12-16 2023-02-28 Genentech Inc Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida
EP1629001A2 (fr) 2003-06-05 2006-03-01 Genentech, Inc. Antagonistes de blys et leurs utilisations
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2004308452A1 (en) * 2003-12-22 2005-07-14 Novartis Vaccines And Diagnostics, Inc. Use of Fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
CA2566745A1 (fr) 2004-05-20 2005-12-01 Zymogenetics, Inc. Procedes de traitement du cancer par polytherapie associant il-21 et des anticorps monoclonaux
EP1753455A2 (fr) 2004-06-04 2007-02-21 Genentech, Inc. Methode de traitement de la sclerose en plaques
BRPI0607351A2 (pt) * 2005-02-15 2009-09-01 Novartis Vaccines & Diagnostic métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (fr) 2005-11-23 2016-12-14 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072333A1 (fr) * 2000-03-24 2001-10-04 Chiron Corporation Methodes destinees a traiter un lymphome non hodgkinien au moyen d'une combinaison d'interleukine 2 avec un anticorps anti-cd20

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072333A1 (fr) * 2000-03-24 2001-10-04 Chiron Corporation Methodes destinees a traiter un lymphome non hodgkinien au moyen d'une combinaison d'interleukine 2 avec un anticorps anti-cd20

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 2; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 250b, ISSN: 0006-4971 *
CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. AUG 1998, vol. 46, no. 6, August 1998 (1998-08-01), pages 318 - 326, ISSN: 0340-7004 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), THUMMALA ANURADHA R ET AL: "A Phase I/II study of Rituxan and interleukin 2 (IL-2) in patients with low grade or mantle cell non Hodgkins lymphoma (NHL): Preliminary results", XP001204186, Database accession no. PREV200200152443 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; June 2002 (2002-06-01), ATKINS M B: "Interleukin-2: Clinical applications", XP009041149, Database accession no. EMB-2002208050 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; August 1998 (1998-08-01), MEROPOL N J ET AL: "Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.", XP001204063, Database accession no. NLM9756416 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2000 (2000-07-01), FEHNIGER T A ET AL: "Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.", XP001204064, Database accession no. NLM10880055 *
JANAKIRAMAN N ET AL: "RITUXIMAB: CORRELATION BETWEEN EFFECTOR CELLS AND CLINICAL ACTIVITYIN NHL", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 10,SUP01 PT01, 15 November 1998 (1998-11-15), pages 337A, XP001009992, ISSN: 0006-4971 *
LEGET G A ET AL: "USE OF RITUXIMAB, THE NEW FDA-APPROVED ANTIBODY", CURRENT OPINION IN ONCOLOGY, CURRENT SCIENCE LTD, US, vol. 10, no. 6, November 1998 (1998-11-01), pages 548 - 551, XP000952702, ISSN: 1040-8746 *
SEMINARS IN ONCOLOGY 2002 UNITED STATES, vol. 29, no. 3 SUPPL. 7, 2002, pages 12 - 17, ISSN: 0093-7754 *
THE JOURNAL OF CLINICAL INVESTIGATION. JUL 2000, vol. 106, no. 1, July 2000 (2000-07-01), pages 117 - 124, ISSN: 0021-9738 *
YIRINEC B ET AL: "Preliminary report on biological effects of rituxan (R) and interleukin-2 (IL-2) in patients with low-grade or mantle cell non-Hodgkins lymphoma (NHL)", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 94, no. 10 suppl 1 part 2, 15 November 1999 (1999-11-15), pages 270b, XP002170813, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
EP1463524A2 (fr) 2004-10-06
AU2002362098A8 (en) 2003-06-23
AU2002362098A1 (en) 2003-06-23
WO2003049694A2 (fr) 2003-06-19
CA2469045A1 (fr) 2003-06-19
WO2003049694A3 (fr) 2003-11-06
JP2005538034A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
EP1463524A4 (fr) Methodes therapeutiques de traitement d'un lymphome non hodgkinien
GB2393202B (en) Methods of well treatment
AU2002348135A1 (en) Methods for the treatment of addiction
GB0129976D0 (en) Treatment method
EP1463495A4 (fr) Agents et procedes de traitement du cancer
GB0118383D0 (en) Therapeutic methods
HUP0302739A3 (en) Method for the treatment of tobacco
GB0124124D0 (en) Methods of treatment
GB0120147D0 (en) Treatment method
GB0210741D0 (en) Methods of therapy
GB0112216D0 (en) Method of treatment
GB0130763D0 (en) Treatment methods
GB0118892D0 (en) Method of treatment
AU2004281077A1 (en) Methods and agents for the treatment of cancer
IL161630A0 (en) Methods of treating endometreosis
GB0126253D0 (en) Treatment method
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2002367463A8 (en) Novel p53bp2 compounds for therapy and diagnosis and methods for using same
AUPR950401A0 (en) Methods for treatment
AU2003905726A0 (en) Methods and agents for the treatment of cancer
GB0126094D0 (en) Method of treatment
GB0125105D0 (en) Method of treatment
GB0116029D0 (en) Method of treatment
GB0111487D0 (en) Method of treatment
AU2002305374A1 (en) Stimulation apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20041228

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 38/20 B

Ipc: 7A 61K 39/395 A

17Q First examination report despatched

Effective date: 20050331

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070270

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

17Q First examination report despatched

Effective date: 20050331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100701

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070270

Country of ref document: HK